Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities

Gut

Volumn 65, Issue 6, 2016, Pages 944-953

  Hedin, Charlotte ^a,b   Van Der Gast, Christopher J ^c   Rogers, Geraint B ^d   Cuthbertson, Leah ^c   McCartney, Sara ^e   Stagg, Andrew J ^b   Lindsay, James O ^b,f   Whelan, Kevin ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

^d FLINDERS UNIVERSITY   (Australia)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DYSBIOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FAECALIBACTERIUM PRAUSNITZII; FECES LEVEL; FEMALE; FLOW CYTOMETRY; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; KIDNEY BIOPSY; MALE; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; PATHOGENESIS; PHENOTYPE; POPULATION ABUNDANCE; PRIORITY JOURNAL; PYROSEQUENCING; RISK FACTOR; SIBLING; T LYMPHOCYTE; BIOPSY; CASE CONTROL STUDY; FECES; GENETICS; INTESTINE; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; PATHOLOGY;

ADOLESCENT; ADULT; BIOPSY; CASE-CONTROL STUDIES; CROHN DISEASE; DYSBIOSIS; FAECALIBACTERIUM PRAUSNITZII; FECES; FEMALE; GENOTYPE; HUMANS; INTESTINAL MUCOSA; INTESTINES; MALE; MICROBIOTA; PHENOTYPE; SIBLINGS;

EID: 84930399071     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308896     Document Type: Article

References (39)

1. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146:1489-99.
2. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-25.
3. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-52.
4. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24.
5. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-31.
6. Harper PH, Lee EC, Kettlewell MG, et al. Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985;26:279-84.
7. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-6.
8. Ghouri YA, Richards DM, Rahimi EF, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014;9:473-87.
9. Benjamin JL, Hedin CR, Koutsoumpas A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011;60:923-9.
10. Calkins BM, Mendeloff AI. Epidemiology of inflammatory bowel disease. Epidemiol Rev 1986;8:60-91.
11. Halfvarson J. Genetics in twins with Crohn's disease: less pronounced than previously believed? Inflamm Bowel Dis 2011;17:6-12.
12. Hedin CR, Stagg AJ, Whelan K, et al. Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention. Gut 2012;61:311-18.
13. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011;60:631-7.
14. Hedin CR, McCarthy NE, Louis P, et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 2014;63:1578-86.
15. van der Gast CJ, Walker AW, Stressmann FA, et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J 2011;5:780-91.
16. Sogin ML, Morrison HG, Huber JA, et al. Microbial diversity in the deep sea and the underexplored "rare biosphere". Proc Natl Acad Sci U S A 2006;103:12115-20.
17. Li K, Bihan M, Yooseph S, et al. Analyses of the microbial diversity across the human microbiome. PLoS One 2012;7:e32118.
18. Le CE, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013;500:541-6.
19. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-4.
20. Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013;105:1907-11.
21. Ismail IH, Oppedisano F, Joseph SJ, et al. Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants. Pediatr Allergy Immunol 2012;23:674-81.
22. Biedermann L, Zeitz J, Mwinyi J, et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One 2013;8:e59260.
23. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011;13:101.
24. Crouch DJ, Goddard GH, Lewis CM. REGENT: a risk assessment and classification algorithm for genetic and environmental factors. Eur J Hum Genet 2013;21:109-11.
25. Goddard GH, Lewis CM. Risk categorization for complex disorders according to genotype relative risk and precision in parameter estimates. Genet Epidemiol 2010;34:624-32.
26. Rogers GB, Cuthbertson L, Hoffman LR, et al. Reducing bias in bacterial community analysis of lower respiratory infections. ISME J 2013;7:697-706.
27. Rogers GB, Kozlowska J, Keeble J, et al. Functional divergence in gastrointestinal microbiota in physically-separated genetically identical mice. Sci Rep 2014;4:5437.
28. Dowd SE, Wolcott RD, Sun Y, et al. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One 2008;3:e3326.
29. R Core Team. R Foundation for Statistical Computing. Vienna A: R: A Language and Environment for Statistical Computing, 2014.
30. Willing B, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that GI microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010;39:1844-54.
31. Rajca S, Grondin V, Louis E, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis 2014;20:978-86.
32. Macfarlane GT, Macfarlane S. Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol 2011;45(Suppl):S120-7.
33. Vinolo MA, Rodrigues HG, Nachbar RT, et al. Regulation of inflammation by short chain fatty acids. Nutrients 2011;3:858-76.
34. Bassaganya-Riera J, Hontecillas R, Horne WT, et al. Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. Clin Nutr 2012;31:721-7.
35. Hansen R, Russell RK, Reiff C, et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am J Gastroenterol 2012;107:1913-22.
36. Rachmilewitz D, Karmeli F, Okon E, et al. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995;37:247-55.
37. Duncan SH, Louis P, Thomson JM, et al. The role of pH in determining the species composition of the human colonic microbiota. Environ Microbiol 2009;11:2112-22.
38. Park JH, Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010;42:570-5.
39. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461:747-53.